View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2014	Mar. 03, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	DVAX
Entity Registrant Name	DYNAVAX TECHNOLOGIES CORP
Entity Central Index Key	0001029142
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		28,914,954
Entity Public Float			$ 267,344,912

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 49,511	$ 23,122
Marketable securities available-for-sale	73,141	166,254
Accounts receivable	727	1,627
Prepaid expenses and other current assets	4,058	1,375
Total current assets	127,437	192,378
Property and equipment, net	7,924	8,706
Goodwill	2,277	2,579
Restricted cash	632	662
Other assets	20	297
Total assets	138,290	204,622
Current liabilities:
Accounts payable	1,159	1,901
Accrued research and development	6,938	2,402
Accrued liabilities	6,317	5,764
Deferred revenues	5,865	6,125
Total current liabilities	20,279	16,192
Deferred revenues, net of current portion	6,900	1,173
Long term debt	9,559
Other long-term liabilities	1,070	963
Total liabilities	37,808	18,328
Commitments and contingencies
Stockholders’ equity:
Common stock: $0.001 par value; 69,500 and 35,000 shares authorized at December 31, 2014 and 2013, respectively; 26,307 and 26,280 shares issued and outstanding at December 31, 2014 and 2013, respectively	26	263
Additional paid-in capital	695,058	688,390
Accumulated other comprehensive loss	(1,669)	(148)
Accumulated deficit	(592,933)	(502,211)
Total stockholders’ equity	100,482	186,294
Total liabilities and stockholders’ equity	138,290	204,622
Series B Convertible Preferred Stock
Stockholders’ equity:
Preferred stock: $0.001 par value Authorized: 5,000 shares; Issued and outstanding: Series B Convertible Preferred Stock — 43 shares at December 31, 2014 and 2013

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Collaboration revenue	$ 7,933	$ 4,929	$ 4,610
Grant revenue	2,688	5,138	3,939
Service and license revenue	411	1,184	1,165
Total revenues	11,032	11,251	9,714
Operating expenses:
Research and development	84,580	50,870	49,146
General and administrative	17,377	25,943	28,164
Unoccupied Facility expense	386	926
Total operating expenses	102,343	77,739	77,310
Loss from operations	(91,311)	(66,488)	(67,596)
Other income (expense):
Interest income	191	116	291
Interest expense	(35)		(2,351)
Other income (expense), net	433	(348)	(293)
Net loss	(90,722)	(66,720)	(69,949)
Preferred stock deemed dividend		(8,469)
Net loss allocable to common stockholders	$ (90,722)	$ (75,189)	$ (69,949)
Net loss per share allocable to common stockholders - basic and diluted	$ (3.45)	$ (3.83)	$ (4.10)
Weighted average shares outstanding used to compute basic and diluted net loss per share allocable to common stockholders	26,289	19,628	17,047

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Preferred Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balances at Dec. 31, 2011	$ 99,880	$ 155		$ 466,276	$ (1,009)	$ (365,542)
Beginning Balances (in shares) at Dec. 31, 2011		15,463
Issuance of common stock upon exercise of stock options and restricted stock awards	1,955	$ 1		1,954
Issuance of common stock upon exercise of stock options and restricted stock awards (In Shares)		122
Issuance of common stock under Employee Stock Purchase Plan	307			307
Issuance of common stock under Employee Stock Purchase Plan (in shares)		14
Proceeds from issuances of common stock and warrants, net of issuance costs	71,780	$ 27		71,753
Proceeds from issuances of common stock and warrants, net of issuance costs (in shares)		2,680
Stock compensation expense	10,439			10,439
Total other comprehensive income (loss)	414				414
Net loss	(69,949)					(69,949)
Ending Balances at Dec. 31, 2012	114,826	$ 183		550,729	(595)	(435,491)
Ending Balances (in shares) at Dec. 31, 2012		18,279
Issuance of common stock upon exercise of stock options and restricted stock awards	112			112
Issuance of common stock upon exercise of stock options and restricted stock awards (In Shares)		11
Issuance of common stock under Employee Stock Purchase Plan	224			224
Issuance of common stock under Employee Stock Purchase Plan (in shares)		13
Restricted Stock Award Delivered (in shares)		12
Issuance of common stock, net of issuance costs	80,999	$ 80		80,919
Issuance of common stock, net of issuance costs (in shares)		7,957
Issuance of Series B convertible preferred stock, net of issuance costs	44,209			44,209
Issuance of Series B convertible preferred stock, net of issuance costs (in shares)			43
Initial expenses related to ATM agreement	(143)			(143)
Warrants exercised (in shares)		8
Stock compensation expense	12,340			12,340
Total other comprehensive income (loss)	447				447
Net loss	(66,720)					(66,720)
Ending Balances at Dec. 31, 2013	186,294	$ 263		688,390	(148)	(502,211)
Ending Balances (in shares) at Dec. 31, 2013		26,280	43
Issuance of common stock upon exercise of stock options and restricted stock awards	49			49
Issuance of common stock upon exercise of stock options and restricted stock awards (In Shares)		5
Reverse stock split		$ (237)		237
Issuance of common stock under Employee Stock Purchase Plan	130			130
Issuance of common stock under Employee Stock Purchase Plan (in shares)		11
Warrants exercised	163			163
Warrants exercised (in shares)		11
Stock compensation expense	6,089			6,089
Total other comprehensive income (loss)	(1,521)				(1,521)
Net loss	(90,722)					(90,722)
Ending Balances at Dec. 31, 2014	$ 100,482	$ 26		$ 695,058	$ (1,669)	$ (592,933)
Ending Balances (in shares) at Dec. 31, 2014		26,307	43

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating activities
Net loss	$ (90,722)	$ (66,720)	$ (69,949)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,404	1,327	1,207
(Gain) loss on disposal of property and equipment	(24)	18	8
Accretion of discounts and amortization of premiums of marketable securities	881	923	1,298
Interest associated with long-term note payable to Symphony Dynamo Holdings LLC (“Holdings")			2,190
Loss on lease	386	926
Stock compensation expense	6,089	12,340	10,439
Changes in operating assets and liabilities:
Accounts receivable	900	(622)	8,522
Prepaid expenses and other current assets	(2,683)	677	(922)
Restricted cash and other assets	277	176	(116)
Accounts payable	(523)	(657)	126
Accrued liabilities and other long term liabilities	4,810	(2,291)	1,916
Deferred revenues	5,467	(4,770)	1,472
Net cash used in operating activities	(73,738)	(58,673)	(43,809)
Investing activities
Purchases of marketable securities	(44,807)	(192,044)	(206,149)
Proceeds from maturities of marketable securities	137,071	142,321	169,387
Purchases of property and equipment, net	(1,667)	(1,629)	(2,931)
Net cash provided by (used in) investing activities	90,597	(51,352)	(39,693)
Financing activities
Proceeds from issuances of common stock		80,856	71,780
Proceeds from issuances of preferred stock		44,209
Proceeds from exercise of stock options and restricted stock awards	49	112	1,955
Proceeds from Employee Stock Purchase Plan	130	224	307
Proceeds from exercise of warrants	163
Proceeds from long-term debt payable to Hercules, net	9,559
Payment of notes payable to Holdings			(15,000)
Net cash provided by financing activities	9,901	125,401	59,042
Effect of exchange rate changes on cash and cash equivalents	(371)	147	118
Net increase (decrease) in cash and cash equivalents	26,389	15,523	(24,342)
Cash and cash equivalents at beginning of year	23,122	7,599	31,941
Cash and cash equivalents at end of year	49,511	23,122	7,599
Non-cash investing and financing activities:
Disposal of fully depreciated property and equipment	841	86	169
Net change in unrealized gain (loss) on marketable securities	$ 32	$ (76)	$ 48

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements include our accounts and those of our wholly-owned subsidiaries. All significant intercompany accounts and transactions among the entities have been eliminated from the consolidated financial statements.

Liquidity and Financial Condition

We have incurred significant operating losses and negative cash flows from operations since our inception. As of December 31, 2014, we had cash, cash equivalents and marketable securities of $122.7 million. We currently estimate that we have sufficient cash resources to meet our anticipated cash needs through at least the next 12 months based on cash, cash equivalents and marketable securities on hand as of December 31, 2014 and anticipated revenues and funding from existing collaboration agreements.

We expect to continue to spend substantial funds in connection with the development and manufacturing of our product candidates, particularly HEPLISAV-B, human clinical trials for our product candidates and additional applications and advancement of our technology. In order to continue these activities, we may need to raise additional funds. This may occur through strategic collaboration and licensing arrangements and/or future public or private debt and equity financings. Sufficient additional funding may not be available on acceptable terms, or at all. If adequate funds are not available in the future, we may need to delay, reduce the scope of or put on hold the HEPLISAV-B program or our other development programs while we seek strategic alternatives.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make informed estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from these estimates.

Reverse Stock Split

All references to numbers of shares of our common stock and per-share information in the accompanying financial statements have been adjusted retroactively to reflect the Company’s ten-for-one reverse stock split effected on November 7, 2014. The par value was not adjusted as a result of the reverse stock split.

Foreign Currency Translation

We consider the local currency to be the functional currency for our international subsidiary, Rhein. Accordingly, assets and liabilities denominated in foreign currencies are translated into U.S. dollars using the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing throughout the year. Currency translation adjustments arising from period to period are charged or credited to accumulated other comprehensive income (loss) in stockholders’ equity. For the years ended December 31, 2014, 2013 and 2012, we reported an unrealized loss of $1.6 million, an unrealized gain of $0.5 million and an unrealized gain of $0.4 million, respectively. Realized gains and losses resulting from currency transactions are included in the consolidated statements of operations. For the years ended December 31, 2014, 2013 and 2012, we reported a gain of $0.4 million, a loss of $0.2 million and a loss of $0.2 million, respectively, resulting from currency transactions in our consolidated statements of operations.

Cash, Cash Equivalents and Marketable Securities

We consider all highly liquid investments purchased with an original maturity of three months or less and that can be liquidated without prior notice or penalty, to be cash equivalents. Management determines the appropriate classification of marketable securities at the time of purchase. In accordance with our investment policy, we invest in short-term money market funds and U.S. government agency securities. We believe these types of investments are subject to minimal credit and market risk.

We have classified our entire investment portfolio as available-for-sale and available for use in current operations and accordingly have classified all investments as short-term. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities, with unrealized gains and losses included in accumulated other comprehensive income (loss) in stockholders’ equity. Realized gains and losses and declines in value, if any, judged to be other than temporary on available-for-sale securities are included in interest income or expense. The cost of securities sold is based on the specific identification method. Management assesses whether declines in the fair value of investment securities are other than temporary. In determining whether a decline is other than temporary, management considers the following factors:

·	Whether the investment has been in a continuous realized loss position for over 12 months;

·	the duration to maturity of our investments;

·	our intention and ability to hold the investments to maturity and if it is not more likely than not that we will be required to sell the investment before recovery of the amortized cost bases;

·	the credit rating, financial condition and near-term prospects of the issuer; and

·	the type of investments made.

To date, there have been no declines in fair value that have been identified as other than temporary.

Concentration of Credit Risk and Other Risks and Uncertainties

We operate in one business segment, which is the discovery and development of biopharmaceutical products. We determine our segments based on the way we organize our business by making operating decisions and assessing performance. In fiscal years 2014, 2013 and 2012, 96%, 89% and 88% of our revenues were earned in the United States, respectively, and the remaining revenues were earned in Germany. As of December 31, 2014 and 2013, 11% and 9%, respectively, of our long-lived assets were located in the United States and the remaining long-lived assets were located in Germany.

Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable securities and accounts receivable. Our policy is to invest cash in institutional money market funds and marketable securities of U.S. government and corporate issuers with high credit quality to limit the amount of credit exposure. We currently maintain a portfolio of cash equivalents and marketable securities in a variety of securities, including short-term money market funds and U.S. government agency securities. We have not experienced any losses on our cash equivalents and marketable securities.

Accounts receivable are recorded at invoice value. We review our exposure to accounts receivable, including the requirement for allowances based on management’s judgment. We have not historically experienced any significant losses. We do not currently require collateral for any of our accounts receivable.

Our products will require approval from the U.S. Food and Drug Administration (“FDA”) and foreign regulatory agencies before commercial sales can commence. There can be no assurance that our products will receive any of these required approvals. The denial or delay of such approvals would have a material adverse impact on our business.

We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of products, product liability, the volatility of our stock price and the need to obtain additional financing.

Long-Lived Assets

Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Repair and maintenance costs are charged to expense as incurred. Leasehold improvements are amortized over the remaining life of the initial lease term or the estimated useful lives of the assets, whichever is shorter.

We evaluate the carrying value of long-lived assets, including intangible assets, whenever events or changes in business circumstances or our planned use of long-lived assets indicate, based on undiscounted future operating cash flows, that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. When an indicator of impairment exists, long-lived assets are written down to their respective fair values. Fair value is determined primarily using the anticipated cash flows discounted at a rate commensurate with the risk involved. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected undiscounted cash flows. No impairments of purchased intangible assets or material impairments of tangible assets have been identified during the years presented.

Goodwill

Our goodwill balance relates to our April 2006 acquisition of Rhein. Goodwill was recorded as the excess purchase price over tangible and intangible assets acquired and liabilities assumed based on their estimated fair value, by applying the acquisition method of accounting. Goodwill is not amortized but is subject to an annual impairment test which consists of a comparison of the fair value of the related reporting unit against its carrying amount including goodwill. If the carrying amount exceeds the fair value, impairment is calculated and recorded as a charge in the consolidated statements of operations. We determined that we have only one operating segment and there are no components of that operating segment that are deemed to be separate reporting units such that we have one reporting unit for purposes of our goodwill impairment testing. We evaluate goodwill for impairment on an annual basis and on an interim basis if events or changes in circumstances between annual impairment tests indicate that the asset might be impaired.

Revenue Recognition

Our revenues consist of amounts earned from collaborations, grants and fees from services and licenses. We enter into license and manufacturing agreements and collaborative research and development arrangements with pharmaceutical and biotechnology partners that may involve multiple deliverables. Our arrangements may include one or more of the following elements: upfront license payments, cost reimbursement for the performance of research and development activities, milestone payments, other contingent payments, contract manufacturing service fees, royalties and license fees. Each deliverable in the arrangement is evaluated to determine whether it meets the criteria to be accounted for as a separate unit of accounting or whether it should be combined with other deliverables. In order to account for the multiple-element arrangements, the Company identifies the deliverables included within the arrangement and evaluates which deliverables represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. We recognize revenue when there is persuasive evidence that an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured.

Non-refundable upfront fees received for license and collaborative agreements entered into and other payments under collaboration agreements where we have continuing performance obligations related to the payments are deferred and recognized over our estimated performance period. Revenue is recognized on a ratable basis, unless we determine that another method is more appropriate, through the date at which our performance obligations are completed. Management makes its best estimate of the period over which we expect to fulfill our performance obligations, which may include clinical development activities. Given the uncertainties of research and development collaborations, significant judgment is required to determine the duration of the performance period. We recognize cost reimbursement revenue under collaborative agreements as the related research and development costs are incurred, as provided for under the terms of these agreements.

Contingent consideration received for the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is defined as an event having all of the following characteristics: (i) there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, (ii) the event can only be achieved based in whole or in part on either the entity’s performance or a specific outcome resulting from the entity’s performance and (iii) if achieved, the event would result in additional payments being due to the entity.

Our license and collaboration agreements with our partners provide for payments to be paid to us upon the achievement of development milestones. Given the challenges inherent in developing biologic products, there is substantial uncertainty whether any such milestones will be achieved at the time we entered into these agreements. In addition, we evaluate whether the development milestones meet the criteria to be considered substantive. The conditions include: (i) the development work is contingent on either of the following: (a) the vendor’s performance to achieve the milestone or (b) the enhancement of the value of the deliverable item or items as a result of a specific outcome resulting from the vendor’s performance to achieve the milestone; (ii) it relates solely to past performance and (iii) it is reasonable relative to all the deliverable and payment terms within the arrangement. As a result of our analysis, we consider our development milestones to be substantive and, accordingly, we expect to recognize as revenue future payments received from such milestones as we achieve each milestone.

Milestone payments that are contingent upon the achievement of substantive at-risk performance criteria are recognized in full upon achievement of those milestone events in accordance with the terms of the agreement and assuming all other revenue recognition criteria have been met. All revenue recognized to date under our collaborative agreements has been nonrefundable.

Our license and collaboration agreements with certain partners also provide for contingent payments to be paid to us based solely upon the performance of our partner. For such contingent payments we expect to recognize the payments as revenue upon receipt, provided that collection is reasonably assured and the other revenue recognition criteria have been satisfied.

Revenues from manufacturing services are recognized upon meeting the criteria for substantial performance and acceptance by the customer.

Revenue from royalty payments is contingent on future sales activities by our licensees. As a result, we recognize royalty revenue when all revenue recognition criteria have been satisfied.

Revenue from government and private agency grants is recognized as the related research expenses are incurred and to the extent that funding is approved. Additionally, we recognize revenue based on the facilities and administrative cost rate reimbursable per the terms of the grant awards.

Research and Development Expenses and Accruals

Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under such arrangements may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed.

We contract with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. Our accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. We may terminate these contracts upon written notice and we are generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances we may be further responsible for termination fees and penalties. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to the Company at that time. There have been no material adjustments to the Company’s prior period accrued estimates for clinical trial activities through December 31, 2014.

Stock-Based Compensation

Stock-based compensation expense for stock options and other stock awards is estimated at the grant date based on the award’s fair value-based measurement and is recognized on a straight-line basis over the award’s vesting period, assuming appropriate forfeiture rates. Our determination of the fair value-based measurement of stock options on the date of grant using an option-pricing model is affected by our stock price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. In the future, as additional empirical evidence regarding these input estimates becomes available, we may change or refine our approach of deriving these input estimates. These changes could impact our fair value-based measurement of stock options granted in the future. Changes in the fair value-based measurement of stock awards could materially impact our operating results.

We selected the Black-Scholes option pricing model as the most appropriate method for determining the estimated fair value-based measurement of our stock options. The Black-Scholes model requires the use of highly subjective and complex assumptions which determine the fair value-based measurement of stock options, including the option’s expected term and the price volatility of the underlying stock. Our current estimate of volatility is based on the historical volatility of our stock price. To the extent volatility in our stock price increases in the future, our estimates of the fair value of options granted in the future could increase, thereby increasing stock-based compensation cost recognized in future periods. We derive the expected term assumption primarily based on our historical settlement experience, while giving consideration to options that have not yet completed a full life cycle. Stock-based compensation cost is recognized only for awards ultimately expected to vest. Our estimate of the forfeiture rate is based primarily on our historical experience. To the extent we revise this estimate in the future, our share-based compensation cost could be materially impacted in the period of revision.

Income Taxes

We account for income taxes using the asset and liability method, under which deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Additionally, we assess the likelihood that deferred tax assets will be recovered as deductions from future taxable income. We have provided a full valuation allowance on our deferred tax assets at December 31, 2014 and 2013 because we believe it is more likely than not that our deferred tax assets will not be realized as of December 31, 2014, and 2013.

Recent Accounting Pronouncements

Accounting Standards Update 2014-09

In May 2014, the FASB issued guidance codified in ASC 606, Revenue Recognition — Revenue from Contracts with Customers, which amends the guidance in former ASC 605, Revenue Recognition. The Company is currently evaluating the impact of the provisions of ASC 606. This standard is effective for public entities for annual and interim periods beginning after December 31, 2016, which will be the Company’s fiscal year 2017.

Fair Value Measurements

12 Months Ended

Dec. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value Measurements

3.	Fair Value Measurements

The Company measures fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

·	Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities;

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

·	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.

The carrying amounts of cash equivalents, accounts receivable, accounts payable and accrued liabilities are considered reasonable estimates of their respective fair value because of their short-term nature. The carrying amount of our long-term debt is considered a reasonable estimate of its respective fair value as it is amortized over its life using the effective interest rate.

Recurring Fair Value Measurements

The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) measured at fair value on a recurring basis as of December 31, 2014 and 2013 (in thousands):

	Level 1		Level 2		Level 3		Total
December 31, 2014
Money market funds	$	46,989	$	-	$	-	$	46,989
U.S. government agency securities		-		73,141		-		73,141
Total	$	46,989	$	73,141	$	-	$	120,130

	Level 1		Level 2		Level 3		Total
December 31, 2013
Money market funds	$	20,013	$	-	$	-	$	20,013
U.S. government agency securities		-		167,597		-		167,597
Total	$	20,013	$	167,597	$	-	$	187,610

Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.

U.S. Government agency securities are measured at fair value using Level 2 inputs. We review trading activity and pricing for these investments as of each measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.

There were no transfers between Level 1 and Level 2 during the twelve months ended December 31, 2014.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Cash, Cash Equivalents and Marketable Securities

12 Months Ended

Dec. 31, 2014

Cash Cash Equivalents And Short Term Investments [Abstract]

Cash, Cash Equivalents and Marketable Securities

4.	Cash, Cash Equivalents and Marketable Securities

Cash equivalents and marketable securities as of December 31, 2014, and 2013 consist of the following (in thousands):

	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
December 31, 2014
Cash and cash equivalents:
Cash	$	2,522	$	-	$	-		$	2,522
Money market funds		46,989		-		-			46,989
Total cash and cash equivalents		49,511		-		-			49,511
Marketable securities available-for-sale:
U.S. government agency securities		73,140		11		(10	)		73,141
Total marketable securities available-for-sale		73,140		11		(10	)		73,141
Total cash, cash equivalents and marketable securities	$	122,651	$	11	$	(10	)	$	122,652
December 31, 2013
Cash and cash equivalents:
Cash	$	1,766	$	-	$	-		$	1,766
Money market funds		20,013		-		-			20,013
U.S. government agency securities		1,343		-		-			1,343
Total cash and cash equivalents		23,122		-		-			23,122
Marketable securities available-for-sale:
U.S. government agency securities		166,285		16		(47	)		166,254
Total marketable securities available-for-sale		166,285		16		(47	)		166,254
Total cash, cash equivalents and marketable securities	$	189,407	$	16	$	(47	)	$	189,376

The maturities of our marketable securities available-for-sale are as follows (in thousands):

	December 31, 2014
	Amortized Cost		Estimated Fair Value
Mature in one year or less	$	72,390	$	72,391
Mature after one year through two years		750		750
	$	73,140	$	73,141

There were no realized gains or losses from the sale of marketable securities in the years ended December 31, 2014, 2013 and 2012. All of our investments are classified as short-term and available-for-sale, as we may not hold our investments until maturity.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2014

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

7.	Commitments and Contingencies

We lease our facilities in Berkeley, California (“Berkeley Lease”) and Düsseldorf, Germany (“Düsseldorf Lease”) under operating leases that expire in June 2018 and March 2023, respectively. The Berkeley Lease provides for periods of escalating rent. The total cash payments over the life of the lease are divided by the total number of months in the lease period and the average rent is charged to expense each month during the lease period. We entered into sublease agreements under the Düsseldorf Lease for a certain portion of the leased space. The sublease income is offset against our rent expense.

During September 2013, we decided not to occupy a portion of our facility in Berkeley, California. As a result, we recorded an estimated unoccupied facility expense of $0.9 million during 2013, representing the present value of the rent payments and other costs associated with the lease, net of estimated sublease income, for the remaining life of the operating lease. During the first three quarters of 2014, we reassessed our timing and ability to sublet a portion of our facility and recorded a total unoccupied facility expense of $0.4 million for the year ended December 31, 2014. In December 2014, we decided to utilize the unoccupied portion of the facility and began to recognize rent expense under the terms noted in the operating lease agreement.

Total net rent expense related to our operating leases for the years ended December 31, 2014, 2013 and 2012, was $1.7 million, $1.9 million and $1.7 million, respectively. Deferred rent was $0.6 million as of December 31, 2014 and 2013. Deferred loss on lease was $0.7 million as of December 31, 2014 and 2013.

Future minimum payments under the non-cancelable portion of our operating leases at December 31, 2014, excluding payments from sublease payments, are as follows (in thousands):

Year ending December 31,
2015	$	2,213
2016		2,264
2017		2,313
2018		1,282
2019		519
Thereafter		1,687
Total	$	10,278

During the fourth quarter of 2004, we established a letter of credit with Silicon Valley Bank as security for our Berkeley Lease in the amount of $0.4 million. The letter of credit remained outstanding as of December 31, 2014, and is collateralized by a certificate of deposit for $0.4 million, which has been included in restricted cash in the consolidated balance sheets as of December 31, 2014 and 2013. Under the terms of the Berkeley Lease, if the total amount of our cash, cash equivalents and marketable securities falls below $20 million for a period of more than 30 consecutive days during the lease term, the amount of the required security deposit will increase to $1.1 million, until such time as our projected cash and cash equivalents will exceed $20 million for the remainder of the lease term, or until our actual cash and cash equivalents remains above $20 million for a period of 12 consecutive months.

We established a letter of credit with Deutsche Bank as security for our Düsseldorf Lease in the amount of approximately 0.2 million Euros. The letter of credit remained outstanding through December 31, 2014 and is collateralized by a certificate of deposit for 0.2 million Euros, which has been included in restricted cash in the consolidated balance sheets as of December 31, 2014 and 2013.

In addition to the non-cancelable commitments included above, we have entered into contractual arrangements that obligate us to make payments to the contractual counterparties upon the occurrence of future events. In addition, in the normal course of operations, we have entered into license and other agreements and intend to continue to seek additional rights relating to compounds or technologies in connection with our discovery, manufacturing and development programs. Under the terms of the agreements, we may be required to pay future up-front fees, milestones and royalties on net sales of products originating from the licensed technologies, if any, or other payments contingent upon the occurrence of future events that cannot reasonably be estimated.

We rely on research institutions, contract research organizations, clinical investigators as well as clinical and commercial material manufacturers of our product candidates. As of December 31, 2014, under the terms of our agreements, including certain agreements relating to the ongoing Phase 3 trial of HEPLISAV-B, we are obligated to make future payments as services are provided of approximately $25.5 million through 2016. These agreements are terminable by us upon written notice. Generally, we are liable only for actual effort expended by the organizations at any point in time during the contract through the notice period.

From time to time, we are involved in claims, suits, and proceedings arising from the ordinary course of our business, including actions with respect to intellectual property claims, commercial claims, and other matters. Such claims, suits, and proceedings are inherently uncertain and their results cannot be predicted with certainty. Regardless of the outcome, such legal proceedings can have an adverse impact on us because of legal costs, diversion of management resources, and other factors. In addition, it is possible that a resolution of one or more such proceedings could result in substantial fines and penalties or orders requiring a change in our business practices, which could in the future materially and adversely affect our financial position, results of operations, or cash flows in a particular period.

Collaborative Research, Development and License Agreements

12 Months Ended

Dec. 31, 2014

Research And Development [Abstract]

Collaborative Research, Development and License Agreements

9.	Collaborative Research, Development and License Agreements

AstraZeneca

In September 2006, we entered into a three year research collaboration and license agreement with AstraZeneca for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease.

In October 2011, we amended our agreement with AstraZeneca to provide that we will conduct initial clinical development of AZD1419 and AstraZeneca agreed to fund all program expenses to cover the cost of development activities through Phase 2a. Under the terms of the amended agreement, we received an initial payment of $3 million in 2011 to begin the clinical development program. In the first quarter of 2012, we received a $2.6 million payment to advance AZD1419 into preclinical toxicology studies, which were completed in the third quarter of 2012. We and AstraZeneca agreed to advance AZD1419 towards a Phase 1 clinical trial, which resulted in a development funding payment of $6 million received in the fourth quarter of 2012.

In January 2014, we amended our agreement with AstraZeneca for the clinical development of AZD1419 whereby responsibility for conducting clinical trials was transferred from Dynavax to AstraZeneca upon completion of the Phase 1 trial. In the first quarter of 2014, we received a $5.4 million payment that was due upon execution of this amended agreement.

In August 2014, we announced the results of a Phase 1 study in which AZD1419 or placebo was delivered by inhalation to 45 healthy volunteers. The primary study objective was to assess the safety of ascending doses of AZD1419 administered weekly for up to 4 weeks. Doses up to 15.4 mg/week were well tolerated and no serious adverse events were observed in treated subjects. Secondary endpoints assessing pharmacodynamics were met, with dose-dependent induction of interferon-regulated genes in sputum and blood cells.

In December 2014, we again amended our agreement with AstraZeneca for the clinical development of AZD1419. Under the terms of this amendment, AstraZeneca will fully fund and Dynavax will conduct a Phase IIa safety and efficacy trial of AZD1419 in patients with asthma. In the fourth quarter of 2014, we received an $8.0 million payment due upon execution of this amended agreement.

Under the terms of this agreement, as amended, we are eligible to receive up to $100 million in additional milestone payments. Additionally, upon commercialization, we are eligible to receive tiered royalties ranging from the mid to high single-digits based on product sales of any products originating from the collaboration. We have the option to co-promote in the United States products arising from the collaboration, if any. AstraZeneca has the right to sublicense its rights upon our prior consent.

Revenue from the $5.4 million payment received in the first quarter of 2014 was deferred and is being recognized over the estimated remaining period of performance, which is approximately 48 months. Revenue from the $8.0 million payment received in the fourth quarter of 2014 was deferred and is being recognized over the estimated remaining period of performance, which is approximately 30 months. Revenue from the $3.0 million initial payment received in 2011 was deferred and is being recognized over the estimated remaining period of performance, which is approximately 74 months. Revenue from the development funding payments is being recognized as the development work is performed.

The following table summarizes the revenues earned under our agreement with AstraZeneca, included as collaboration revenue in our consolidated statements of operations (in thousands):


	Year ended December 31,
	2014		2013		2012
Initial payment	$	681	$	720	$	720
Subsequent payment		2,554		-		-
Performance of research activities		2,174		2,507		2,462
Total	$	5,409	$	3,227	$	3,182

As of December 31, 2014 and 2013, total deferred revenue from the initial payment, subsequent payment and development funding payments was $12.8 million and $4.8 million, respectively.

Absent early termination, the agreement will expire when all of AstraZeneca’s payment obligations expire. AstraZeneca has the right to terminate the agreement at any time upon prior written notice and either party may terminate the agreement early upon written notice if the other party commits an uncured material breach of the agreement.

GlaxoSmithKline

In December 2008, we entered into a worldwide strategic alliance with GSK to discover, develop and commercialize TLR inhibitors. Under the terms of the arrangement, as amended, we agreed to conduct research and early clinical development of product candidates and GSK received an option to license those candidates. Under the collaboration, we conducted a Phase 1 clinical trial in the lead TLR 7/9 program with DV1179 to assess its safety and tolerability in healthy volunteers followed by a Phase 1b/2a study of safety and pharmacodynamics in patients with systematic lupus erythematosus (“SLE”).

In August 2014, we announced results of the Phase 1b/2a clinical trial in which DV1179 did not meet the primary or secondary pharmacodynamic endpoints. The agreement with GSK expired in November 2014. The Company has regained global rights to continue the development of DV1179 and other TLR 7/9 inhibitors for all indications.

Under the terms of the arrangement, as amended, we received an initial payment of $10 million in 2008. The deliverables under this arrangement did not have stand-alone value and so did not qualify as separate units of accounting. Revenue from the initial payment from GSK was deferred and is being recognized over the estimated period of performance under the agreement, initially estimated to be seven years. In 2013 we reevaluated and revised the estimated period of performance under the agreement resulting in the recognition of $1.1 million of additional revenue for the year ended December 31, 2014.

The following table summarizes the revenues recognized under our agreement with GSK, included as collaboration revenue in our consolidated statements of operations (in thousands):

	Year ended December 31,
	2014		2013		2012
Initial payment	$	2,524	$	1,702	$	1,428
Total	$	2,524	$	1,702	$	1,428

As of December 31, 2014, no deferred revenue relating to the initial payment remains. As of December 31, 2013, deferred revenue relating to the initial payment was $2.5 million.

National Institutes of Health (“NIH”) and Other Funding

We have been awarded various grants from the NIH and the NIH’s National Institute of Allergy and Infectious Disease (“NIAID”) in order to fund research. The awards are related to specific research objectives and we earn revenue as the related research expenses are incurred. We have earned revenue during the years ended December 31, 2014 and 2013 from the following awards:

·	August 2014, NIH awarded us $0.2 million to fund research in developing a transgenic mouse model to study human TLR9 role in disease.

·	September 2013, NIH awarded us $0.2 million to fund research in developing TLR antagonists for therapy of hepatic fibrosis and cirrhosis.

·	June 2012, NIH awarded us $0.6 million to fund research in screening for inhibitors of TLR8 for treatment of autoimmune diseases.

·	May 2012, NIH awarded us $0.4 million to fund development of TLR8 inhibitors for treatment of rheumatoid arthritis.

·	July 2011, NIH awarded us $0.6 million to fund research in preclinical models of skin autoimmune inflammation.

August 2010, NIAID awarded us a grant to take a systems biology approach to study the differences between individuals who do or do not respond to vaccination against the hepatitis B virus. This study will be one of several projects conducted under a grant to the Baylor Institute of Immunology Research in Dallas as part of the Human Immune Phenotyping Centers program. We have been awarded a total of $1.4 million under this grant.

·	September 2008, NIAID awarded us a five-year $17 million contract to develop our ISS technology using TLR9 agonists as vaccine adjuvants. The contract supports adjuvant development for anthrax as well as other disease models.

The following table summarizes the revenues recognized under the various arrangements with the NIH and NIAID, included as grant revenue in our consolidated statements of operations (in thousands):


	Year ended December 31,
	2014		2013		2012
NIAID contracts	$	2,095	$	4,103	$	3,571
All other NIH contracts		593		1,035		368
Total grant revenue	$	2,688	$	5,138	$	3,939

Long-Term Debt

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

Long-Term Debt

10.	Long-Term Debt

In December 2014, we entered into a Loan and Security Agreement (“Loan Agreement”) with Hercules Technology Growth Capital, Inc. (“Hercules”) under which we may borrow up to $40.0 million in two tranches.

We drew down the first tranche of $10.0 million upon closing of the transaction on December 23, 2014. The second tranche, of $30.0 million, can be drawn at our option any time prior to September 30, 2015, but only if we have achieved certain milestones relating to the ongoing HEPLISAV–B Phase 3 study (“Milestone A”). We plan to use the proceeds received under the Loan Agreement to provide additional funding for HEPLISAV–B development and pre-commercialization activities, as a potential source of funding for clinical trials for its cancer immunotherapeutic product candidate, SD-101, and for general corporate purposes.

The interest rate for each tranche in the Loan Agreement is calculated at a rate equal to the greater of either (i) 9.75% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.25%, and (ii) 9.75%. Payments under the Loan Agreement are interest only until February 1, 2016 (which will be extended until August 1, 2016, if we achieve Milestone A on or before September 30, 2015, and which will be extended until February 1, 2017, if we meet certain additional HEPLISAV-B Phase 3 related milestones (“Milestone B”) on or before August 1, 2016). The interest only period will be followed by equal monthly payments of principal and interest amortized over a 30 month schedule through the scheduled maturity date on July 1, 2018 (which would be extended through January 1, 2019 if we achieve Milestone A on or before September 30, 2015 or Milestone B on or before August 1, 2016) (the “Loan Maturity Date”). The entire principal balance, including a balloon payment of principal, as applicable, will be due and payable on the Loan Maturity Date, which we recorded as a liability and debt discount at the origination of the loan.

A final payment equal to $840,000 (if an aggregate of $10.0 million is advanced under the Loan Agreement) or $2,400,000 (if an aggregate of $40.0 million is advanced under the Loan Agreement) will be due on the Loan Maturity Date, or such earlier date specified in the Loan Agreement. Our obligations under the Loan Agreement are secured by a security interest in substantially all of its assets, other than its intellectual property. Additionally, we paid a $400,000 facility charge to Hercules. The debt issuance costs and final payment fee are being amortized and accreted, respectively, to interest expense over the term of the term loan using the effective interest method.

In addition, Hercules was granted the right, at its discretion, to participate in any Subsequent Financing in an aggregate amount of up to $1,500,000 (that is, a maximum amount of $1,500,000 with respect to all subsequent financings collectively) on the same terms, conditions and pricing afforded to others participating in any such Subsequent Financing.

The Hercules Loan Agreement includes customary affirmative and restrictive covenants, but does not include any financial maintenance covenants, and also includes standard events of default. At December 31, 2014, we were in compliance with all loan covenants. Upon an event of default, including a change of control, Hercules has the option to accelerate repayment of the loan, including payment of any applicable prepayment charges, which is 1.50% of the outstanding loan balance and accrued but unpaid interest.

As of December 31, 2014, we had outstanding borrowings under the Hercules Loan Agreement of $10.0 million, with a carrying value of $9.6 million, net of the debt discounts of the $0.4 million facility charge and a $45 thousand commitment fee. Amortization of the debt discount was immaterial for the year ended December 31, 2014.

The following table summarizes our outstanding future minimum payments associated with our long-term debt as of December 31, 2014 (in thousands):

Obligations:	Total		2015		2016-2017		2018-2019		2020 and Thereafter
Principal payments on long-term debt	$	10,000	$	-	$	7,425	$	2,575	$	-
Interest payments on long-term debt		2,343		929		1,328		86		-
Total	$	12,343	$	929	$	8,753	$	2,661	$	-

Net Loss Per Share

12 Months Ended

Dec. 31, 2014

Earnings Per Share [Abstract]

Net Loss Per Share

11.	Net Loss Per Share

Basic net loss per share allocable to common stockholders is calculated by dividing the net loss allocable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share allocable to common stockholders is computed by dividing the net loss allocable to common stockholders by the weighted-average number of common shares outstanding during the period and giving effect to all potentially dilutive common shares using the treasury-stock method. For purposes of this calculation, common stock subject to repurchase by us, outstanding stock options, stock awards, warrants and Series B Convertible Preferred Stock are considered to be potentially dilutive common shares and are only included in the calculation of diluted net loss per share allocable to common stockholders when their effect is dilutive.

	December 31,
	2014			2013			2012
Basic and diluted net loss per share (in thousands, except per share amounts):
Numerator:
Net loss		(90,722	)		(66,720	)		(69,949	)
Preferred stock deemed dividend		-			(8,469	)		-
Net loss allocable to common stockholders	$	(90,722	)	$	(75,189	)	$	(69,949	)
Denominator for basic and diluted net loss per share allocable to common stockholders:
Weighted-average common shares outstanding		26,289			19,628			17,047
Basic and diluted net loss per share allocable to common stockholders	$	(3.45	)	$	(3.83	)	$	(4.10	)

Outstanding warrants, stock options, Series B Convertible Preferred Stock and stock subject to repurchase by us under stock awards were excluded from the calculation of net loss per share allocable to common stockholders as the effect of their inclusion would have been anti-dilutive.

	December 31,
	2014		2013		2012
Outstanding securities not included in diluted net loss per share calculation (in thousands):
Stock options and stock awards		1,998		1,704		1,556
Series B Convertible Preferred Stock (as converted to common stock)		4,343		4,343		-
Warrants		1,081		1,246		1,271
		7,422		7,293		2,827

Preferred Stock, Common Stock and Warrants

12 Months Ended

Dec. 31, 2014

Preferred Stock Common Stock And Warrants [Abstract]

Preferred Stock, Common Stock and Warrants

12.	Preferred Stock, Common Stock and Warrants

Preferred Stock Outstanding

As of December 31, 2014 there were 5,000,000 shares of preferred stock authorized and 43,430 shares of Series B Convertible Preferred Stock outstanding.

In October 2013 the Company sold 43,430 shares of $0.001 par value Series B Convertible Preferred Stock for a purchase price of $1,075 per share and gross proceeds of approximately $46.7 million in an underwritten public offering. After issuance costs of approximately $2.5 million, the net proceeds from the offering were approximately $44.2 million.

Each share of Series B Convertible Preferred Stock is convertible into 100 shares of common stock at any time at the holder’s option. However, the holder is prohibited from converting the Series B Convertible Preferred Stock into shares of common stock if, as a result of such conversion, the holder and its affiliates would own more than 9.98% of the total number of shares of common stock then issued and outstanding. In the event of the Company’s liquidation, dissolution, or winding up, holders of Series B Convertible Preferred Stock will receive a payment equal to $0.001 per share before any proceeds are distributed to the common stockholders. Shares of Series B Convertible Preferred Stock generally have no voting rights, except as required by law and except that the consent of holders of a majority of the outstanding Series B Convertible Preferred Stock is required to amend the terms of the Series B Convertible Preferred Stock. Holders of Series B Convertible Preferred Stock are not entitled to receive any dividends, unless and until specifically declared by the Company’s board of directors. The Series B Convertible Preferred Stock ranks senior to the Company’s common stock as to distributions of assets upon the Company’s liquidation, dissolution or winding up, whether voluntarily or involuntarily. The Series B Convertible Preferred Stock may rank senior to, on parity with or junior to any class or series of the Company’s capital stock created in the future depending upon the specific terms of such future stock issuance.

The fair value of the common stock into which the Series B Convertible Preferred Stock is convertible exceeded the allocated purchase price of the Series B Convertible Preferred Stock by $8.5 million on the date of issuance, for which the Company recorded a deemed dividend. The Company recognized the deemed dividend equal to the number of shares of Series B Convertible Preferred Stock sold on October 30, 2013 multiplied by the difference between the value of the common stock and the Series B Convertible Preferred Stock conversion price per share on that date. The dividend was reflected as a one-time, non-cash, deemed dividend to the holders of Series B Convertible Preferred Stock on the date of issuance, which is the date the stock first became convertible.

Preferred Share Purchase Rights

On November 4, 2008, our Board of Directors declared a dividend of one preferred share purchase right (a “Right”) for each outstanding share of our Common Stock, par value $0.001 per share (the “Common Shares”). The dividend was payable on November 17, 2008 to the stockholders of record on that date. Each Right entitles the registered holder to purchase from us one one-hundredth of a share of Series A Junior Participating Preferred Stock, par value $0.001 per share (the “Preferred Shares”), at a price of $6.00 per one one-hundredth of a Preferred Share, subject to adjustment. Upon the acquisition of, or announcement of the intent to acquire, 20 percent or more of our outstanding Common Shares by a person, entity or group of affiliated or associated persons (“Acquiring Person”), each holder of a Right, other than Rights held by the Acquiring Person, will have the right to purchase that number of Common Shares having a market value of two times the exercise price of the Right. If we are acquired in a merger or other business combination transaction or 50 percent or more of our assets or earning power are sold to an Acquiring Person, each holder of a Right will thereafter have the right to purchase, at the then current exercise price of the Right, that number of shares of common stock of the acquiring company which at the time of such transaction will have a market value of two times the exercise price of the Right. The Rights plan is intended to maximize the value of the Company in the event of an unsolicited attempt to take over the Company in a manner or on terms not approved by the Company’s Board of Directors. The Rights will expire on November 17, 2018, unless the Rights are earlier redeemed or exchanged by the Company.

Common Stock Outstanding

On November 10, 2014, we entered into an At Market Issuance Sales Agreement (the “ATM Agreement”) with Cowen and Company, LLC (“Cowen”) under which we may offer and sell our common stock having aggregate sales proceeds of up to $50,000,000 from time to time through Cowen as our sales agent. Sales of our common stock through Cowen, if any, will be made by means of ordinary brokers’ transactions on the NASDAQ Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by us and Cowen. Cowen will use commercially reasonable efforts to sell our common stock from time to time, based upon instructions from us (including any price, time or size limits or other customary parameters or conditions we may impose). We will pay Cowen a commission of up to 3.0% of the gross sales proceeds of any common stock sold through Cowen under the Agreement. No sales of our common stock have taken place under this ATM Agreement as of December 31, 2014.

In October 2013 we completed an underwritten public offering of 7,957,000 shares of our common stock to the public at $1.075 per share. The gross proceeds to us from this offering were approximately $85.5 million. After deducting issuance costs of approximately $4.5 million, the net proceeds from the offering were approximately $80.9 million.

Warrants

As of December 31, 2014, warrants to purchase an aggregate of approximately 1,100,000 shares of our common stock were outstanding. The warrants are exercisable at a weighted average price of $15.00 per share and will expire on April 16, 2015. During the years ended December 31, 2014, and 2013, warrants were exercised to purchase an aggregate of approximately 11,000 and 25,000 shares, respectively, of our common stock.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Equity Plans and Stock-Based Compensation

12 Months Ended

Dec. 31, 2014

Share Based Compensation [Abstract]

Equity Plans and Stock-Based Compensation

13.	Equity Plans and Stock-Based Compensation

Stock Plans

Under the 2004 Stock Incentive Plan options to purchase 349,853 shares of common stock remained outstanding as of December 31, 2014

Under the 2010 Employment Inducement Award Plan options to purchase 12,500 shares of common stock remained outstanding as of December 31, 2014

The 2011 Equity Incentive Plan (“2011 Plan”) was approved by the Company’s stockholders and adopted in January 2011. On May 29, 2013, the stockholders of the Company approved an amendment to the 2011 Plan to increase the number of shares of common stock authorized for issuance under the plan by 1,000,000. The 2011 Plan, as amended, provides for the issuance of up to 2,500,000 shares of our common stock to employees and non-employees of the Company and became effective on January 6, 2011. The 2011 Plan is administered by our Board of Directors, or a designated committee of the Board of Directors, and awards granted under the 2011 Plan have a term of 10 years unless earlier terminated by the Board of Directors. After the adoption of the 2011 Plan, no additional awards were granted under either the 2004 Plan or the Inducement Plan. As of January 6, 2011, all shares subject to awards outstanding under the 2004 Plan and Inducement Plan that expire or are forfeited will be included in the reserve for the 2011 Plan to the extent such shares would otherwise return to such plans. As of December 31, 2014, options to purchase 1,456,927 shares of common stock remained outstanding under the 2011 Plan. As of December 31, 2014, there were 1,023,365 shares of common stock reserved for issuance under the 2011 Plan.

Activity under our stock plans is set forth below:

	Shares Underlying Outstanding Options (in thousands)			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (in thousands)
Balance at December 31, 2013		1,576		$	31.66
Options granted		582			16.75
Options exercised		(5	)		9.90
Options cancelled:
Options forfeited (unvested)		(86	)		23.94
Options cancelled (vested)		(247	)		30.51
Balance at December 31, 2014		1,820			27.48		6.07	$	833
Vested and expected to vest at December 31, 2014		1,820			27.48		6.07	$	833
Exercisable at December 31, 2014		1,040			33.10		4.02	$	649

The total intrinsic value of stock options exercised during the years ended December 31, 2014, 2013 and 2012 was, $0.1 million, $0.3 million and $2.7 million, respectively. The total intrinsic value of exercised stock options is calculated based on the difference between the exercise price and the quoted market price of our common stock as of the close of the exercise date.

The total fair value of stock options vested during the years ended December 31, 2014, 2013 and 2012 was, $5.6 million, $12.1 million and $9.6 million, respectively.

Our non-vested stock awards are comprised of restricted stock units granted with performance and time-based vesting criteria. A summary of the status of non-vested restricted stock units as of December 31, 2014, and activities during 2014 are summarized as follows:

	Number of Shares (In thousands)			Weighted-Average Grant-Date Fair Value
Non-vested as of December 31, 2013		128		$	39.30
Granted		155		$	17.92
Vested	-			$	-
Forfeited or expired		(104	)	$	42.02
Non-vested as of December 31, 2014		179		$	17.13

Stock-based compensation expense related to restricted stock units was approximately $0.6 million for the year ended December 31, 2014. The aggregate intrinsic value of the restricted stock units outstanding as of December 31, 2014, based on our stock price on that date, was $3.0 million.

The weighted average grant-date fair value of restricted stock units granted during the years ended December 31, 2014, 2013 and 2012 was, $17.92, $12.30 and $42.30, respectively. The total fair value of restricted stock units vested during the years ended December 31, 2013 and 2012 was$0.1 million and $0.2 million, respectively. No restricted stock units vested during 2014.

Stock-Based Compensation

Under our stock-based compensation plans, option awards generally vest over a four-year period contingent upon continuous service and expire ten years from the date of grant (or earlier upon termination of continuous service). The Company has also granted performance-based equity awards to certain of our employees under the 2011 Plan, the 2004 Plan and the Inducement Plan. As of December 31, 2014, 76,247 shares were outstanding related to options and restricted stock units subject to these performance-based vesting criteria. The fair value of each option is estimated on the date of grant using the Black-Scholes option valuation model and the following weighted-average assumptions:

	Stock Options									Employee Stock Purchase Plan
	Year Ended December 31,									Year Ended December 31,
	2014			2013			2012			2014			2013			2012
Weighted-average fair value	$	15.16		$	24.15		$	33.00		$	7.45		$	9.30		$	35.40
Risk-free interest rate		1.8	%		1.1	%		0.5	%		0.2	%		0.2	%		0.2	%
Expected life (in years)		5.9			5.9			4.2			1.2			1.3			1.1
Volatility		1.4			1.4			1.6			0.9			0.8			1.6

Expected volatility is based on historical volatility of our stock price. The expected life of options granted is estimated based on historical option exercise and employee termination data, while giving consideration to options that have not yet completed a full life cycle. Our senior management, who hold a majority of the options outstanding, and other employees were grouped and considered separately for valuation purposes. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield is zero percent for all years and is based on our history and expectation of dividend payouts.

Compensation expense is based on awards ultimately expected to vest and reflects estimated forfeitures. For equity awards with time-based vesting, the fair value is amortized to expense on a straight-line basis over the vesting periods. For equity awards with performance-based vesting criteria, the fair value is amortized to expense when the achievement of the vesting criteria becomes probable.

We recognized the following amounts of stock-based compensation expense (in thousands):

	Year Ended December 31,
	2014		2013		2012
Employees and directors stock-based compensation expense	$	6,062	$	11,828	$	10,439
Non-employees stock-based compensation expense		27		512		-
Total	$	6,089	$	12,340	$	10,439

	Year Ended December 31,
	2014		2013		2012
Research and development	$	2,868	$	4,228	$	3,514
General and administrative		3,221		8,112		6,925
Total	$	6,089	$	12,340	$	10,439

During the year ended December 31, 2013, we recognized $1.3 million in additional stock-based compensation expense due to the modification of the terms of stock options for five employees. Stock based compensation expense recognized for the year ended December 31, 2013 included $4.9 million related to employee severance arrangements and $0.5 million for awards to non-employees.

As of December 31, 2014, the total unrecognized compensation cost related to non-vested stock options and awards deemed probable of vesting, including all stock options with time-based vesting, net of estimated forfeitures, amounted to $13.5 million, which is expected to be recognized over the remaining weighted-average vesting period of 2.7 years. As of December 31, 2014, the total unrecognized compensation cost related to non-vested stock options not deemed probable of vesting, net of estimated forfeitures, amounted to $0.4 million.

As of December 31, 2014, the total unrecognized compensation cost related to shares of our common stock under the Purchase Plan, amounted to $0.1 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.6 years.

Employee Stock Purchase Plan

In January 2004, the Board of Directors and stockholders adopted the 2004 Employee Stock Purchase Plan. As of December 31, 2014, 99,600 shares were approved for issuance under the 2004 Employee Stock Purchase Plan, subject to adjustment for a stock split, or any future stock dividend or other similar change in our common stock or capital structure. To date, employees have acquired 94,104 shares of our common stock under the 2004 Employee Stock Purchase Plan. As of December 31, 2014, 5,496 shares of our common stock remained available for future purchases.

In May 2014, stockholders of the Company approved the 2014 Employee Stock Purchase Plan (the “Purchase Plan”), pursuant to which the Company may issue up to 50,000 shares of its common stock to its employees. The Purchase Plan provides for the purchase of common stock by eligible employees and became effective on May 28, 2014. The purchase price per share is the lesser of (i) 85% of the fair market value of the common stock on the commencement of the offer period (generally, the fifteenth day in February or August) or (ii) 85% of the fair market value of the common stock on the exercise date, which is the last day of a purchase period (generally, the fourteenth day in February or August).

Income Taxes

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Income Taxes

15.	Income Taxes

Consolidated income (loss) before provision for income taxes consisted of the following (in thousands):

	Year Ended December 31,
	2014			2013			2012
U.S.	$	(91,121	)	$	(67,004	)	$	(70,792	)
Non U.S.		399			284			843
Total	$	(90,722	)	$	(66,720	)	$	(69,949	)

No income tax expense was recorded for the years ended December 31, 2014, 2013 and 2012 due to net operating loss carryforwards to offset the net income at Dynavax Europe and a valuation allowance which offsets the deferred tax assets. The difference between the consolidated income tax benefit and the amount computed by applying the federal statutory income tax rate to the consolidated loss before income taxes was as follows (in thousands):

	Year Ended December 31,
	2014			2013			2012
Income tax benefit at federal statutory rate	$	(30,818	)	$	(22,678	)	$	(23,650	)
State tax		1,204			(178	)		(89	)
Business credits		(1,484	)		(2,515	)		-
Deferred compensation charges		2,710			3,072			1,002
Change in valuation allowance		28,093			22,354			21,966
Other		295			(55	)		771
Total income tax expense	$	-		$	-		$	-

Deferred tax assets and liabilities as of December 31, 2014 and 2013 consisted of the following (in thousands):

	December 31,
	2014			2013
Deferred tax assets:
Net operating loss carry forwards	$	178,008		$	147,655
Research tax credit carry forwards		22,914			21,336
Accruals and reserves		9,053			9,501
Capitalized research costs		8,601			10,662
Deferred revenue		654			2,486
Other		1,531			1,255
Total deferred tax assets		220,761			192,895
Less valuation allowance		(220,544	)		(192,733	)
Net deferred tax assets		217			162
Deferred tax liabilities:
Fixed Assets		(217	)		(162	)
Total deferred tax liabilities		(217	)		(162	)
Net deferred tax assets	$	-		$	-

The tax benefit of net operating losses, temporary differences and credit carryforwards is required to be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a full valuation allowance. The valuation allowance increased by $27.8 million, $22.5 million and $22.0 million during the years ended December 31, 2014, 2013 and 2012, respectively. The amount of the valuation allowance for deferred tax assets associated with excess tax deductions from stock based compensation arrangements that will be allocated to contributed capital if the future tax benefits are subsequently recognized is $0.3 million.

We intend to postpone remittance of all or part of net investment (including earnings) indefinitely (i.e., essentially permanently reinvest). As of December 31, 2014, we have not recognized U.S. deferred income taxes as we have cumulative total undistributed losses for non-U.S. subsidiaries.

We have not recorded deferred income taxes applicable to undistributed earnings of a foreign subsidiary that are indefinitely reinvested in foreign operations. Generally, such earnings become subject to U.S. tax upon the remittance of dividends and under certain other circumstances. It is not practicable to estimate the amount of the deferred tax liability on such undistributed earnings.

As of December 31, 2014, we had federal net operating loss carryforwards of approximately $479.1 million, which will expire in the years 2018 through 2034 and federal research and development tax credits of approximately $16.4 million, which expire in the years 2015 through 2034.

As of December 31, 2014, we had net operating loss carryforwards for California state income tax purposes of approximately $202.2 million, which expire in the years 2015 through 2034, and California state research and development tax credits of approximately $12.7 million which do not expire.

As of December 31, 2014, we had net operating loss carryforwards for foreign income tax purposes of approximately $23.1 million, which do not expire.

Uncertain Income Tax positions

The total amount of unrecognized tax benefits as of December 31, 2014 is $2.4 million. If recognized, none of the unrecognized tax benefits would affect the effective tax rate.

The following table summarizes the activity related to the Company’s unrecognized tax benefits:

Balance at December 31, 2013	$	-
Tax positions related to the current year
Additions		-
Reductions		-
Tax positions related to the prior year
Additions		(2,426	)
Reductions		-
Balance at December 31, 2014	$	(2,426	)

Our policy is to account for interest and penalties, if any, as a component of general and administrative expense. As of the December 31, 2014, the Company had no interest related to unrecognized tax benefits. No amounts of penalties related to unrecognized tax benefits were recognized in the provision for income taxes.

The Tax Reform Act of 1986 limits the annual use of net operating loss and tax credit carryforwards in certain situations where changes occur in stock ownership of a company. In the event the Company has a change in ownership, as defined, the annual utilization of such carryforwards could be limited. Due to past equity issuances and changes in ownership of Dynavax common stock, we believe that our ability to use some of our net operating losses and tax credits in the future may be limited.

We are subject to income tax examinations for U.S. federal and state income taxes from 1996 forward. We are subject to tax examination in Germany from 2010 forward.

Selected Quarterly Financial Data

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Financial Data

16.	Selected Quarterly Financial Data (Unaudited; in thousands, except per share amounts)

	Year Ended December 31, 2014
	Q1			Q2			Q3			Q4
Revenues	$	3,498		$	3,048		$	2,209		$	2,277
Net loss	$	(13,840	)	$	(24,777	)	$	(29,819	)	$	(22,286	)
Net loss allocable to common stockholders	$	(13,840	)	$	(24,777	)	$	(29,819	)	$	(22,286	)
Basic and diluted net loss per share allocable to common stockholders	$	(0.53	)	$	(0.94	)	$	(1.13	)	$	(0.85	)
Shares used to compute basic and diluted net loss per share allocable to common stockholders		26,283			26,286			26,291			26,298

	Year Ended December 31, 2013
	Q1			Q2			Q3			Q4
Revenues	$	2,085		$	3,392		$	2,927		$	2,847
Net loss	$	(20,825	)	$	(17,164	)	$	(15,675	)	$	(13,056	)
Net loss allocable to common stockholders	$	(20,825	)	$	(17,164	)	$	(15,675	)	$	(21,525	)
Basic and diluted net loss per share allocable to common stockholders	$	(1.14	)	$	(0.94	)	$	(0.86	)	$	(0.91	)
Shares used to compute basic and diluted net loss per share allocable to common stockholders		18,285			18,291			18,302			23,588

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Basis of Presentation

Liquidity and Financial Condition

Use of Estimates

Reverse Stock Split

Foreign Currency Translation

Cash, Cash Equivalents, and Marketable Securities

Cash, Cash Equivalents and Marketable Securities

(1)	Whether the investment has been in a continuous realized loss position for over 12 months;

(2)	the duration to maturity of our investments;

(3)	our intention and ability to hold the investments to maturity and if it is not more likely than not that we will be required to sell the investment before recovery of the amortized cost bases;

(4)	the credit rating, financial condition and near-term prospects of the issuer; and

(5)	the type of investments made.

To date, there have been no declines in fair value that have been identified as other than temporary.

Concentration of Credit Risk and Other Risks and Uncertainties

Long-Lived Assets

Goodwill

Revenue Recognition

Revenues from manufacturing services are recognized upon meeting the criteria for substantial performance and acceptance by the customer.

Revenue from royalty payments is contingent on future sales activities by our licensees. As a result, we recognize royalty revenue when all revenue recognition criteria have been satisfied.

Research and Development Expenses and Accruals

Stock-Based Compensation

Income Taxes

Recent Accounting Pronouncements

Accounting Standards Update 2014-09

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value Hierarchy for Financial Assets Measured at Fair Value on Recurring Basis

	Level 1		Level 2		Level 3		Total
December 31, 2014
Money market funds	$	46,989	$	-	$	-	$	46,989
U.S. government agency securities		-		73,141		-		73,141
Total	$	46,989	$	73,141	$	-	$	120,130

	Level 1		Level 2		Level 3		Total
December 31, 2013
Money market funds	$	20,013	$	-	$	-	$	20,013
U.S. government agency securities		-		167,597		-		167,597
Total	$	20,013	$	167,597	$	-	$	187,610

Cash, Cash Equivalents and Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2014

Cash Cash Equivalents And Short Term Investments [Abstract]

Summary of Cash, Cash Equivalents and Marketable Securities

Cash equivalents and marketable securities as of December 31, 2014, and 2013 consist of the following (in thousands):

	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
December 31, 2014
Cash and cash equivalents:
Cash	$	2,522	$	-	$	-		$	2,522
Money market funds		46,989		-		-			46,989
Total cash and cash equivalents		49,511		-		-			49,511
Marketable securities available-for-sale:
U.S. government agency securities		73,140		11		(10	)		73,141
Total marketable securities available-for-sale		73,140		11		(10	)		73,141
Total cash, cash equivalents and marketable securities	$	122,651	$	11	$	(10	)	$	122,652
December 31, 2013
Cash and cash equivalents:
Cash	$	1,766	$	-	$	-		$	1,766
Money market funds		20,013		-		-			20,013
U.S. government agency securities		1,343		-		-			1,343
Total cash and cash equivalents		23,122		-		-			23,122
Marketable securities available-for-sale:
U.S. government agency securities		166,285		16		(47	)		166,254
Total marketable securities available-for-sale		166,285		16		(47	)		166,254
Total cash, cash equivalents and marketable securities	$	189,407	$	16	$	(47	)	$	189,376

Maturities of Marketable Securities Available-for-Sale

The maturities of our marketable securities available-for-sale are as follows (in thousands):

	December 31, 2014
	Amortized Cost		Estimated Fair Value
Mature in one year or less	$	72,390	$	72,391
Mature after one year through two years		750		750
	$	73,140	$	73,141

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Collaborative Research and Development Agreements (Tables)

12 Months Ended

Dec. 31, 2014

National Institutes Of Health

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues recognized under the various arrangements with the NIH and NIAID, included as grant revenue in our consolidated statements of operations (in thousands):


	Year ended December 31,
	2014		2013		2012
NIAID contracts	$	2,095	$	4,103	$	3,571
All other NIH contracts		593		1,035		368
Total grant revenue	$	2,688	$	5,138	$	3,939

Agreement With Gsk

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues recognized under our agreement with GSK, included as collaboration revenue in our consolidated statements of operations (in thousands):

	Year ended December 31,
	2014		2013		2012
Initial payment	$	2,524	$	1,702	$	1,428
Total	$	2,524	$	1,702	$	1,428

Astra Zeneca

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues earned under our agreement with AstraZeneca, included as collaboration revenue in our consolidated statements of operations (in thousands):


	Year ended December 31,
	2014		2013		2012
Initial payment	$	681	$	720	$	720
Subsequent payment		2,554		-		-
Performance of research activities		2,174		2,507		2,462
Total	$	5,409	$	3,227	$	3,182

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2014

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

	December 31,
	2014			2013			2012
Basic and diluted net loss per share (in thousands, except per share amounts):
Numerator:
Net loss		(90,722	)		(66,720	)		(69,949	)
Preferred stock deemed dividend		-			(8,469	)		-
Net loss allocable to common stockholders	$	(90,722	)	$	(75,189	)	$	(69,949	)
Denominator for basic and diluted net loss per share allocable to common stockholders:
Weighted-average common shares outstanding		26,289			19,628			17,047
Basic and diluted net loss per share allocable to common stockholders	$	(3.45	)	$	(3.83	)	$	(4.10	)

	December 31,
	2014		2013		2012
Outstanding securities not included in diluted net loss per share calculation (in thousands):
Stock options and stock awards		1,998		1,704		1,556
Series B Convertible Preferred Stock (as converted to common stock)		4,343		4,343		-
Warrants		1,081		1,246		1,271
		7,422		7,293		2,827

Equity Plans and Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2014

Share Based Compensation [Abstract]

Option Activity under Stock-Based Compensation Plans

Activity under our stock plans is set forth below:

	Shares Underlying Outstanding Options (in thousands)			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (in thousands)
Balance at December 31, 2013		1,576		$	31.66
Options granted		582			16.75
Options exercised		(5	)		9.90
Options cancelled:
Options forfeited (unvested)		(86	)		23.94
Options cancelled (vested)		(247	)		30.51
Balance at December 31, 2014		1,820			27.48		6.07	$	833
Vested and expected to vest at December 31, 2014		1,820			27.48		6.07	$	833
Exercisable at December 31, 2014		1,040			33.10		4.02	$	649

Summary of Restricted Stock Units Activity

	Number of Shares (In thousands)			Weighted-Average Grant-Date Fair Value
Non-vested as of December 31, 2013		128		$	39.30
Granted		155		$	17.92
Vested	-			$	-
Forfeited or expired		(104	)	$	42.02
Non-vested as of December 31, 2014		179		$	17.13

Fair Value-Based Measurements and Weighted-Average Assumptions

The fair value of each option is estimated on the date of grant using the Black-Scholes option valuation model and the following weighted-average assumptions:

	Stock Options									Employee Stock Purchase Plan
	Year Ended December 31,									Year Ended December 31,
	2014			2013			2012			2014			2013			2012
Weighted-average fair value	$	15.16		$	24.15		$	33.00		$	7.45		$	9.30		$	35.40
Risk-free interest rate		1.8	%		1.1	%		0.5	%		0.2	%		0.2	%		0.2	%
Expected life (in years)		5.9			5.9			4.2			1.2			1.3			1.1
Volatility		1.4			1.4			1.6			0.9			0.8			1.6

Stock-Based Compensation Expense

We recognized the following amounts of stock-based compensation expense (in thousands):

	Year Ended December 31,
	2014		2013		2012
Employees and directors stock-based compensation expense	$	6,062	$	11,828	$	10,439
Non-employees stock-based compensation expense		27		512		-
Total	$	6,089	$	12,340	$	10,439

	Year Ended December 31,
	2014		2013		2012
Research and development	$	2,868	$	4,228	$	3,514
General and administrative		3,221		8,112		6,925
Total	$	6,089	$	12,340	$	10,439

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Component of Consolidated Income (Loss) Before Provision for Income Taxes

Consolidated income (loss) before provision for income taxes consisted of the following (in thousands):

	Year Ended December 31,
	2014			2013			2012
U.S.	$	(91,121	)	$	(67,004	)	$	(70,792	)
Non U.S.		399			284			843
Total	$	(90,722	)	$	(66,720	)	$	(69,949	)

Difference Between Consolidated Income Tax Benefit and Amount Computed by Federal Statutory Income Tax Rate

	Year Ended December 31,
	2014			2013			2012
Income tax benefit at federal statutory rate	$	(30,818	)	$	(22,678	)	$	(23,650	)
State tax		1,204			(178	)		(89	)
Business credits		(1,484	)		(2,515	)		-
Deferred compensation charges		2,710			3,072			1,002
Change in valuation allowance		28,093			22,354			21,966
Other		295			(55	)		771
Total income tax expense	$	-		$	-		$	-

Component of Deferred Tax Assets and Liabilities

Deferred tax assets and liabilities as of December 31, 2014 and 2013 consisted of the following (in thousands):

	December 31,
	2014			2013
Deferred tax assets:
Net operating loss carry forwards	$	178,008		$	147,655
Research tax credit carry forwards		22,914			21,336
Accruals and reserves		9,053			9,501
Capitalized research costs		8,601			10,662
Deferred revenue		654			2,486
Other		1,531			1,255
Total deferred tax assets		220,761			192,895
Less valuation allowance		(220,544	)		(192,733	)
Net deferred tax assets		217			162
Deferred tax liabilities:
Fixed Assets		(217	)		(162	)
Total deferred tax liabilities		(217	)		(162	)
Net deferred tax assets	$	-		$	-

Schedule of Unrecognized Tax Benefits

The following table summarizes the activity related to the Company’s unrecognized tax benefits:

Balance at December 31, 2013	$	-
Tax positions related to the current year
Additions		-
Reductions		-
Tax positions related to the prior year
Additions		(2,426	)
Reductions		-
Balance at December 31, 2014	$	(2,426	)

Selected Quarterly Financial Data (Tables)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Financial Data

	Year Ended December 31, 2014
	Q1			Q2			Q3			Q4
Revenues	$	3,498		$	3,048		$	2,209		$	2,277
Net loss	$	(13,840	)	$	(24,777	)	$	(29,819	)	$	(22,286	)
Net loss allocable to common stockholders	$	(13,840	)	$	(24,777	)	$	(29,819	)	$	(22,286	)
Basic and diluted net loss per share allocable to common stockholders	$	(0.53	)	$	(0.94	)	$	(1.13	)	$	(0.85	)
Shares used to compute basic and diluted net loss per share allocable to common stockholders		26,283			26,286			26,291			26,298

	Year Ended December 31, 2013
	Q1			Q2			Q3			Q4
Revenues	$	2,085		$	3,392		$	2,927		$	2,847
Net loss	$	(20,825	)	$	(17,164	)	$	(15,675	)	$	(13,056	)
Net loss allocable to common stockholders	$	(20,825	)	$	(17,164	)	$	(15,675	)	$	(21,525	)
Basic and diluted net loss per share allocable to common stockholders	$	(1.14	)	$	(0.94	)	$	(0.86	)	$	(0.91	)
Shares used to compute basic and diluted net loss per share allocable to common stockholders		18,285			18,291			18,302			23,588

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2014 USD ($) Segment	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Cash, cash equivalents and marketable securities	$ 122.7
Reverse stock split	ten-for-one
Reverse stock split effective date	Nov. 07, 2014
Number of operating segment \| Segment	1
United States
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Percentage of revenue earned	96.00%	89.00%	88.00%
Percentage of long lived assets	11.00%	9.00%
Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Cash equivalents original maturity period	3 months
Rhein
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Currency translation adjustments	$ (1.6)	$ 0.5	$ 0.4
Currency transaction gain (loss)	$ 0.4	$ (0.2)	$ (0.2)

Component of Property and Equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property Plant And Equipment [Line Items]
Manufacturing equipment	$ 8,171	$ 8,968
Lab equipment	6,473	7,227
Computer equipment	2,196	1,962
Furniture and fixtures	1,070	1,056
Leasehold improvements	5,690	6,048
Assets in progress	935	762
Property, Plant and Equipment, Gross	24,535	26,023
Less accumulated depreciation and amortization	(16,611)	(17,317)
Total	$ 7,924	$ 8,706
Manufacturing Equipment \| Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	5 years
Manufacturing Equipment \| Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	14 years
Lab Equipment \| Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	5 years
Lab Equipment \| Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	13 years
Computer Equipment
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	3 years
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	3 years
Leasehold Improvements \| Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	5 years
Leasehold Improvements \| Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Lives (In years)	7 years

Commitments and Contingencies - Additional Information (Detail) $ in Thousands, € in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2004 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2014 EUR (€)	Dec. 31, 2013 EUR (€)
Loss Contingencies [Line Items]
Unoccupied facility expense		$ 386	$ 926
Rent expense, net		1,700	1,900	$ 1,700
Deferred rent		600	600
Deferred gain (loss) on lease		(700)	(700)
Cash, cash equivalents and marketable securities		122,700
Future payments obligation		$ 25,500
Deutsche Bank Securities
Loss Contingencies [Line Items]
Letter of credit pledged as security \| €					€ 0.2
Collateralized certificate of deposit \| €					€ 0.2	€ 0.2
Berkeley, California (the "Berkeley Lease")
Loss Contingencies [Line Items]
Operating leases expiration date		2018-06
Unoccupied facility expense		$ 400	900
Dusseldorf, Germany (the "Dusseldorf Lease")
Loss Contingencies [Line Items]
Operating leases expiration date		2023-03
Berkeley, California (the "Berkeley Lease")
Loss Contingencies [Line Items]
Letter of credit pledged as security	$ 400
Collateralized certificate of deposit		$ 400	$ 400
Terms of the lease		If the total amount of our cash, cash equivalents and marketable securities falls below $20 million for a period of more than 30 consecutive days during the lease term, the amount of the required security deposit will increase to $1.1 million, until such time as our projected cash and cash equivalents will exceed $20 million for the remainder of the lease term, or until our actual cash and cash equivalents remains above $20 million for a period of 12 consecutive months.
Berkeley, California (the "Berkeley Lease") \| Contingency, B
Loss Contingencies [Line Items]
Contingency period for cash, cash equivalents and marketable securities	12 months
Berkeley, California (the "Berkeley Lease") \| Contingency, B \| Minimum
Loss Contingencies [Line Items]
Cash, cash equivalents and marketable securities	$ 20,000
Berkeley, California (the "Berkeley Lease") \| Contingency, A
Loss Contingencies [Line Items]
Increase in amount of the security deposit	$ 1,100
Berkeley, California (the "Berkeley Lease") \| Contingency, A \| Minimum
Loss Contingencies [Line Items]
Contingency period for cash, cash equivalents and marketable securities	30 days
Berkeley, California (the "Berkeley Lease") \| Contingency, A \| Maximum
Loss Contingencies [Line Items]
Cash, cash equivalents and marketable securities	$ 20,000

Collaborative Research Development and License Agreements - Additional Information (Detail) $ in Thousands		1 Months Ended				3 Months Ended				12 Months Ended
	Aug. 31, 2014 USD ($) Workers	Oct. 31, 2011 USD ($)	Dec. 31, 2008 USD ($)	Sep. 30, 2008 USD ($)	Sep. 30, 2006	Dec. 31, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2012 USD ($)	Mar. 31, 2012 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Sep. 30, 2013 USD ($)	Jun. 30, 2012 USD ($)	May 31, 2012 USD ($)	Jul. 31, 2011 USD ($)	Aug. 31, 2010 USD ($)
Deferred Revenue Arrangement [Line Items]
Number of healthy workers placebo was delivered by inhalation \| Workers	45
Description of doses well tolerated										15.4 mg/week
Additional revenue recognized										$ 1,100
Revenue from milestone payment						$ 8,000	$ 5,400						$ 3,000
Deferred revenue											$ 2,500
National Institutes Of Health
Deferred Revenue Arrangement [Line Items]
Grants receivable	$ 200
Glaxo Smith Kline
Deferred Revenue Arrangement [Line Items]
Collaboration Revenue			$ 10,000
Hepatic Fibrosis and Cirrhosis \| National Institutes Of Health
Deferred Revenue Arrangement [Line Items]
Grants receivable														$ 200
Autoimmune Disease \| National Institutes Of Health
Deferred Revenue Arrangement [Line Items]
Grants receivable															$ 600
Rheumatoid Arthritis \| National Institutes Of Health
Deferred Revenue Arrangement [Line Items]
Grants receivable																$ 400
Skin Autoimmune Inflammation \| National Institutes Of Health
Deferred Revenue Arrangement [Line Items]
Grants receivable																	$ 600
Amendment
Deferred Revenue Arrangement [Line Items]
Collaboration Revenue						$ 8,000	$ 5,400
Amendment \| Maximum
Deferred Revenue Arrangement [Line Items]
Additional revenue recognized										100,000
Amendment \| Advance the program following completion of Phase 2a
Deferred Revenue Arrangement [Line Items]
Collaboration Revenue								$ 6,000	$ 2,600
Astra Zeneca
Deferred Revenue Arrangement [Line Items]
Research collaboration and license agreement period					3 years
Collaboration Revenue		$ 3,000
Deferred revenue recognition period						30 months	48 months						74 months
Revenue from milestone payment										2,174	2,507	$ 2,462
Deferred revenue						$ 12,800				$ 12,800	$ 4,800
National Institute Of Allergy And Infectious Diseases \| Hepatitis B Virus
Deferred Revenue Arrangement [Line Items]
Grants receivable																		$ 1,400
National Institute Of Allergy And Infectious Diseases \| Iss Technology
Deferred Revenue Arrangement [Line Items]
Research collaboration and license agreement period				5 years
Grants receivable				$ 17,000

Long-Term Debt - Additional Information (Detail)	12 Months Ended
Long-Term Debt - Additional Information (Detail)	Dec. 31, 2014 USD ($) TRANCHES	Sep. 30, 2015 USD ($)	Dec. 23, 2014 USD ($)
Debt Instrument [Line Items]
Debt instrument, interest rate	9.75%
Debt instrument, interest rate terms	The interest rate for each tranche in the Loan Agreement is calculated at a rate equal to the greater of either (i) 9.75% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.25%, and (ii) 9.75%
Debt instrument, payment terms	Payments under the Loan Agreement are interest only until February 1, 2016 (which will be extended until August 1, 2016, if we achieve Milestone A on or before September 30, 2015, and which will be extended until February 1, 2017, if we meet certain additional HEPLISAV-B Phase 3 related milestones (“Milestone B”) on or before August 1, 2016). The interest only period will be followed by equal monthly payments of principal and interest amortized over a 30 month schedule through the scheduled maturity date on July 1, 2018 (which would be extended through January 1, 2019 if we achieve Milestone A on or before September 30, 2015 or Milestone B on or before August 1, 2016) (the “Loan Maturity Date”).
Debt instrument, maturity date	Jul. 01, 2018
Debt instrument, extension date	Jan. 01, 2019
Final minimum repayment of debt	$ 2,400,000
Advance payment on loan agreement	40,000,000
Facility charge to Hercules	$ 400,000
Prime Rate
Debt Instrument [Line Items]
Debt instrument, interest rate	9.75%
Debt instrument, basis spread on variable rate	5.25%
First Tranche
Debt Instrument [Line Items]
Final minimum repayment of debt	$ 840,000
Advance payment on loan agreement	10,000,000
Hercules Technology Growth Capital, Inc. (“Hercules”)
Debt Instrument [Line Items]
Debt under Loan Agreement	$ 40,000,000
Number of tranches for loan and security agreement \| TRANCHES	2
Maximum capacity of subsequent financing	$ 1,500,000
Debt instrument prepayment charge	1.50%
Outstanding borrowings	$ 10,000,000
Carrying value debt	9,600,000
Debt instrument, discount of the facility charge	400,000
Debt instrument commitment fee	$ 45,000
Hercules Technology Growth Capital, Inc. (“Hercules”) \| First Tranche
Debt Instrument [Line Items]
Debt under Loan Agreement			$ 10,000,000
Hercules Technology Growth Capital, Inc. (“Hercules”) \| Second Tranche \| Scenario Forecast
Debt Instrument [Line Items]
Debt under Loan Agreement		$ 30,000,000

Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Basic and diluted net loss per share (in thousands, except per share amounts):
Net loss	$ (22,286)	$ (29,819)	$ (24,777)	$ (13,840)	$ (13,056)	$ (15,675)	$ (17,164)	$ (20,825)	$ (90,722)	$ (66,720)	$ (69,949)
Preferred stock deemed dividend										(8,469)
Net loss allocable to common stockholders	$ (22,286)	$ (29,819)	$ (24,777)	$ (13,840)	$ (21,525)	$ (15,675)	$ (17,164)	$ (20,825)	$ (90,722)	$ (75,189)	$ (69,949)
Denominator for basic and diluted net loss per share allocable to common stockholders:
Weighted-average common shares outstanding	26,298	26,291	26,286	26,283	23,588	18,302	18,291	18,285	26,289	19,628	17,047
Net loss per share allocable to common stockholders - basic and diluted	$ (0.85)	$ (1.13)	$ (0.94)	$ (0.53)	$ (0.91)	$ (0.86)	$ (0.94)	$ (1.14)	$ (3.45)	$ (3.83)	$ (4.10)
Outstanding securities not included in diluted net loss per share calculation (in thousands):
Outstanding securities not included in diluted net loss per share calculation									7,422	7,293	2,827
Series B Convertible Preferred Stock
Outstanding securities not included in diluted net loss per share calculation (in thousands):
Outstanding securities not included in diluted net loss per share calculation									4,343	4,343
Stock Options and Stock Awards
Outstanding securities not included in diluted net loss per share calculation (in thousands):
Outstanding securities not included in diluted net loss per share calculation									1,998	1,704	1,556
Warrant
Outstanding securities not included in diluted net loss per share calculation (in thousands):
Outstanding securities not included in diluted net loss per share calculation									1,081	1,246	1,271

Preferred Stock, Common Stock and Warrants - Additional Information (Detail) - USD ($)			1 Months Ended	12 Months Ended
	Nov. 10, 2014	Nov. 04, 2008	Oct. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Preferred Stock Common Stock And Warrants [Line Items]
Preferred stock, shares authorized				5,000,000	5,000,000
Preferred stock, shares outstanding				43,430
Issuance of common stock, net of issuance costs (in shares)			7,957,000
Preferred stock, par value		$ 0.001		$ 0.001	$ 0.001
Public offering net price per share			$ 1.075
Common stock, par value		$ 0.001		$ 0.001	$ 0.001
Dividends payable date		Nov. 17, 2008
Preferred shares price		$ 6.00
Rights expiration date		Nov. 17, 2018
Warrants to purchase common stock				1,100,000
Warrants exercise price				$ 15.00
Number Of Warrants Exercised During Period				11,000	25,000
Common Stock
Preferred Stock Common Stock And Warrants [Line Items]
Issuance of common stock, net of issuance costs (in shares)					7,957,000
Gross proceeds from issuance of stock			$ 85,500,000
Issuance costs			4,500,000
Net proceeds from offering			$ 80,900,000
Minimum
Preferred Stock Common Stock And Warrants [Line Items]
Percentage of common shares outstanding		20.00%
Percentage of assets		50.00%
Maximum \| Cowen
Preferred Stock Common Stock And Warrants [Line Items]
Common stock sales agreement aggregate sales proceeds	$ 50,000,000
Commission on gross sales proceeds of common stock	3.00%
Series B Convertible Preferred Stock
Preferred Stock Common Stock And Warrants [Line Items]
Preferred stock, shares outstanding				43,430	43,430
Issuance of common stock, net of issuance costs (in shares)			43,430
Preferred stock, par value			$ 0.001
Public offering net price per share			$ 1.075
Gross proceeds from issuance of stock			$ 46,700,000
Issuance costs			2,500,000
Net proceeds from offering			$ 44,200,000
Convertible common stock shares				100
Convertible preferred stock, terms of conversion				The holder is prohibited from converting the Series B Convertible Preferred Stock into shares of common stock if, as a result of such conversion, the holder and its affiliates would own more than 9.98% of the total number of shares of common stock then issued and outstanding.
Convertible preferred stock, settlement terms				In the event of the Company’s liquidation, dissolution, or winding up, holders of Series B Convertible Preferred Stock will receive a payment equal to $0.001 per share before any proceeds are distributed to the common stockholders.
Maximum percentage of shares of common stock issued and outstanding from conversion of preferred stock				9.98%
Convertible common stock exceeded allocated purchase price of preferred stock				$ 8,500,000

Equity Plans and Stock-Based Compensation - Additional Information (Detail) $ / shares in Units, $ in Millions		1 Months Ended			12 Months Ended
	May 29, 2013 shares	May 31, 2014 shares	Jan. 31, 2011 shares	Jan. 31, 2004	Dec. 31, 2014 USD ($) $ / shares shares	Dec. 31, 2013 USD ($) Employee $ / shares shares	Dec. 31, 2012 USD ($) $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares of Common Stock outstanding \| shares					1,820,000	1,576,000
Total intrinsic value of options exercised \| $					$ 0.1	$ 0.3	$ 2.7
Total fair value of stock options vested \| $					$ 5.6	$ 12.1	$ 9.6
Options and restricted stock units outstanding \| shares					76,247
Expected dividend yield					0.00%
Number of employees under stock option \| Employee						5
Total unrecognized compensation cost related to non-vested equity awards \| $					$ 0.4
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved and approved for issuance \| shares					99,600
Total unrecognized compensation cost related to non-vested equity awards \| $					$ 0.1
Total unrecognized compensation cost, weighted-average vesting period					1 year 7 months 6 days
Shares issued to employees \| shares		50,000			94,104
Shares remaining available for future purchases \| shares					5,496
Employee Stock Purchase Plan \| The commencement of the offer period (generally, the fifteenth day in February or August
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase price per share as percentage of fair market value of common stock				85.00%
Employee Stock Purchase Plan \| The exercise date, which is the last day of a purchase period (generally, the fourteenth day in February or August)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase price per share as percentage of fair market value of common stock				85.00%
Employee
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized stock-based compensation expense \| $						$ 4.9
Non Employee Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized stock-based compensation expense \| $						0.5
Additional
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized stock-based compensation expense \| $						$ 1.3
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense related to restricted stock \| $					$ 0.6
Aggregate intrinsic value \| $					$ 3.0
Grant date fair value of restricted stock \| $ / shares					$ 17.92	$ 12.30	$ 42.30
Total fair value of restricted stock units \| $					$ 0.0	$ 0.1	$ 0.2
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expiration period					10 years
Options vesting period					4 years
2004 Stock Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares of Common Stock outstanding \| shares					349,853
2010 Employment Inducement Award Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares of Common Stock outstanding \| shares					12,500
2011 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares of Common Stock outstanding \| shares					1,456,927
Expiration period			10 years
Shares reserved and approved for issuance \| shares					1,023,365
2011 Plan \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of common stock shares \| shares			2,500,000
Increase in the aggregate number of shares of common stock authorized for issuance \| shares	1,000,000
Time Based Vesting Schedule
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized compensation cost related to non-vested equity awards \| $					$ 13.5
Total unrecognized compensation cost, weighted-average vesting period					2 years 8 months 12 days

Option Activity under Stock Plans (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2014 USD ($) $ / shares shares
Number of Options Outstanding
Beginning balance \| shares	1,576
Options granted \| shares	582
Options exercised \| shares	(5)
Ending balance \| shares	1,820
Vested and expected to vest at end of period \| shares	1,820
Exercisable at end of period \| shares	1,040
Weighted-Average Price Per Share
Beginning balance \| $ / shares	$ 31.66
Options granted \| $ / shares	16.75
Options exercised \| $ / shares	9.90
Ending balance \| $ / shares	27.48
Vested and expected to vest at end of period \| $ / shares	27.48
Exercisable at end of period \| $ / shares	$ 33.10
Weighted Average Remaining Contractual Life (In years)
Balance at December 31, 2014	6 years 26 days
Outstanding options vested and expected to vest at end of period	6 years 26 days
Options exercisable at end of period	4 years 7 days
Aggregate Intrinsic Value
Balance at December 31, 2014 \| $	$ 833
Outstanding options (vested and expected to vest) at end of period \| $	833
Options exercisable at end of period \| $	$ 649
Unvested
Number of Options Outstanding
Options cancelled \| shares	(86)
Weighted-Average Price Per Share
Options cancelled \| $ / shares	$ 23.94
Vested
Number of Options Outstanding
Options cancelled \| shares	(247)
Weighted-Average Price Per Share
Options cancelled \| $ / shares	$ 30.51

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]
Income tax expense	$ 0	$ 0	$ 0
Increase (decrease) in valuation allowance	27,800,000	$ 22,500,000	$ 22,000,000
Amount of valuation allowance for deferred tax assets allocated to contributed capital	300,000
Unrecognized tax benefits	2,426,000
Unrecognized tax benefits would affect the effective tax rate	0
Interest related to unrecognized tax benefits	0
Penalties related to unrecognized tax benefits	0
Federal
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 479,100,000
Federal \| Minimum
Income Tax Disclosure [Line Items]
Net operating loss carryforwards, expiration year	2018
Federal \| Maximum
Income Tax Disclosure [Line Items]
Net operating loss carryforwards, expiration year	2034
Federal \| Research And Development
Income Tax Disclosure [Line Items]
Tax credit carryforward amount	$ 16,400,000
Federal \| Research And Development \| Minimum
Income Tax Disclosure [Line Items]
Tax credit carryforward amount, expiration year	2015
Federal \| Research And Development \| Maximum
Income Tax Disclosure [Line Items]
Tax credit carryforward amount, expiration year	2034
California State
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 202,200,000
California State \| Minimum
Income Tax Disclosure [Line Items]
Net operating loss carryforwards, expiration year	2015
California State \| Maximum
Income Tax Disclosure [Line Items]
Net operating loss carryforwards, expiration year	2034
California State \| Research And Development
Income Tax Disclosure [Line Items]
Tax credit carryforward amount	$ 12,700,000
Foreign
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 23,100,000

Component of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carry forwards	$ 178,008	$ 147,655
Research tax credit carry forwards	22,914	21,336
Accruals and reserves	9,053	9,501
Capitalized research costs	8,601	10,662
Deferred revenue	654	2,486
Other	1,531	1,255
Total deferred tax assets	220,761	192,895
Less valuation allowance	(220,544)	(192,733)
Net deferred tax assets	217	162
Deferred tax liabilities:
Fixed Assets	(217)	(162)
Total deferred tax liabilities	$ (217)	$ (162)

Organization - Additional Information (Detail)	12 Months Ended
Organization - Additional Information (Detail)	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Date of Acquisition	Apr. 30, 2006
Business Acquisition, Description of Acquired Entity	In April 2006, we completed the acquisition of Rhein Biotech GmbH (“Rhein” or “Dynavax Europe”), a wholly-owned subsidiary in Düsseldorf, Germany.

Component of Current Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Accrued Liabilities Abstract
Payroll and related expenses	$ 4,613	$ 3,639
Legal expenses	224	339
Third party research expenses	5,898	900
Third party development expenses	1,000	1,313
Third party regulatory expenses	40	189
Other accrued liabilities	1,480	1,786
Total	$ 13,255	$ 8,166

Symphony Dynamo, Inc. - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 30, 2009	Dec. 31, 2014	Apr. 18, 2006
SDI
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Investments in SDI			$ 50,000,000
Ownership percentage by parent			100.00%
Business acquisition contingent consideration percentage	50.00%
Business acquisition upfront payment	$ 50,000,000
Milestone payments		$ 0
Holdings
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Ownership percentage by parent			100.00%

Difference between Consolidated Income Tax Benefit and Amount Computed by Federal Statutory Income Tax Rate (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Income tax benefit at federal statutory rate	$ (30,818,000)	$ (22,678,000)	$ (23,650,000)
State tax	1,204,000	(178,000)	(89,000)
Business credits	(1,484,000)	(2,515,000)
Deferred compensation charges	2,710,000	3,072,000	1,002,000
Change in valuation allowance	28,093,000	22,354,000	21,966,000
Other	295,000	(55,000)	771,000
Total income tax expense	$ 0	$ 0	$ 0

Subsequent Event - Additional Information (Detail) - Subsequent Event	Feb. 26, 2015 shares
Series B Convertible Preferred Stock
Subsequent Event [Line Items]
Conversion of Stock, Shares Converted	26,000
Common Stock
Subsequent Event [Line Items]
Conversion of Stock, Shares Converted	2,600,000

Fair Value Hierarchy for Financial Assets Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets	$ 120,130	$ 187,610
Fair Value, Inputs, Level 1
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets	46,989	20,013
Fair Value, Inputs, Level 2
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets	73,141	167,597
Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets	46,989	20,013
Money Market Funds \| Fair Value, Inputs, Level 1
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets	46,989	20,013
U.S. Government Agency Securities
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets	73,141	167,597
U.S. Government Agency Securities \| Fair Value, Inputs, Level 2
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets	$ 73,141	$ 167,597

Fair Value Measurements - Additional Information (Detail)	Dec. 31, 2014 USD ($)
Fair Value Disclosures [Abstract]
Transfers between level 1 and level 2	$ 0

Summary of Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Detail) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	$ 122,651	$ 189,407
Unrealized Gains	11	16
Unrealized Losses	(10)	(47)
Estimated Fair Value	122,652	189,376
Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	49,511	23,122
Estimated Fair Value	49,511	23,122
Marketable Securities Available-for-Sale
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	73,140	166,285
Unrealized Gains	11	16
Unrealized Losses	(10)	(47)
Estimated Fair Value	73,141	166,254
Cash \| Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	2,522	1,766
Estimated Fair Value	2,522	1,766
Money Market Funds \| Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	46,989	20,013
Estimated Fair Value	46,989	20,013
U.S. Government Agency Securities \| Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost		1,343
Estimated Fair Value		1,343
U.S. Government Agency Securities \| Marketable Securities Available-for-Sale
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	73,140	166,285
Unrealized Gains	11	16
Unrealized Losses	(10)	(47)
Estimated Fair Value	$ 73,141	$ 166,254

Summary of Amortized Cost and Estimated Fair Value of Marketable Securities Available-for-Sale (Detail) $ in Thousands	Dec. 31, 2014 USD ($)
Amortized Cost
Mature in one year or less	$ 72,390
Mature after one year through two years	750
Total amortized cost	73,140
Estimated Fair Value
Mature in one year or less	72,391
Mature after one year through two years	750
Total estimated fair value	$ 73,141

Future Minimum Payments Under Non-Cancelable Portion of Operating Leases (Detail) $ in Thousands	Dec. 31, 2014 USD ($)
Commitments And Contingencies Disclosure [Abstract]
2015	$ 2,213
2016	2,264
2017	2,313
2018	1,282
2019	519
Thereafter	1,687
Total	$ 10,278

Schedule of Outstanding Future Minimum Payments of Long-Term Debt (Detail) $ in Thousands	Dec. 31, 2014 USD ($)
Debt Instrument [Line Items]
Total	$ 12,343
2015	929
2016-2017	8,753
2018-2019	2,661
Principal payments on long-term debt
Debt Instrument [Line Items]
Total	10,000
2016-2017	7,425
2018-2019	2,575
Interest payments on long-term debt
Debt Instrument [Line Items]
Total	2,343
2015	929
2016-2017	1,328
2018-2019	$ 86